We
report
the
assembly
of
poly(ethylene
glycol)
nanoparticles
(PEG
NPs)
and
optimize
their
surface
chemistry
to
minimize
formation
protein
coronas
immunogenicity
for
improved
biodistribution.
PEG
NPs
cross-linked
with
disulfide
bonds
are
synthesized
utilizing
zeolitic
imidazolate
framework-8
as
templates,
which
subsequently
modified
molecules
different
end
groups
(carboxyl,
methoxy,
or
amino)
vary
chemistry.
Among
modifications,
amino
residual
carboxyl
form
a
pair
zwitterionic
structures
on
NPs,
adsorption
proteins
(e.g.,
immunoglobulin,
complement
proteins)
maximize
blood
circulation
time.
The
influence
preexisting
antibodies
in
mice
pharmacokinetics
is
negligible,
demonstrates
resistance
anti-PEG
inhibition
accelerated
clearance
phenomenon.
This
research
highlights
importance
PEGylated
design
delivery
systems
reveals
translational
potential
cancer
therapy.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(4), P. 701 - 701
Published: Feb. 19, 2025
Glioblastoma
multiforme
(GBM)
is
a
highly
malignant
brain
tumor
that
has
bleak
outlook
despite
existing
treatments
such
as
surgery,
radiation,
and
chemotherapy.
The
utilization
of
nanoparticles
for
drug
delivery
presents
promising
method
by
which
to
improve
the
effectiveness
treatment
while
reducing
harmful
effects
on
entire
body.
This
review
examines
application
in
GBM,
focusing
different
types
nanoparticles,
including
lipid-based,
polymeric,
metallic,
those
under
development.
Every
variety
analyzed
its
distinct
characteristics
therapeutic
capacity.
Lipid-based
liposomes
solid
lipid
enhance
transport
medicines
are
not
soluble
water
have
shown
considerable
potential
preclinical
investigations.
Polymeric
benefits
terms
controlled
release
targeted
distribution,
whereas
metallic
both
therapy
imaging.
In
current
we
would
like
emphasize
ways
medicine
delivery,
specifically
enhancing
penetration
blood-brain
barrier
(BBB),
targeting
tumors,
enabling
release.
Additionally,
also
discuss
clinical
discoveries,
highlighting
achievements
obstacles
process
converting
these
technologies
into
effective
GBM.
study
offers
thorough
examination
present
status
prospects
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 24, 2025
Background
Neuraminidase-1
(NEU1)
is
an
enzyme
that
breaks
down
sialic
acids
on
glycoproteins
and
glycolipids.
Aberrant
expression
of
NEU1
has
been
linked
to
the
progression
numerous
malignancies,
including
liver
cancer.
Oseltamivir
phosphate
(OP)
a
drug
used
treat
prevent
influenza,
which
specifically
inhibits
NEU1.
However,
molecular
mechanisms
in
cancer
potential
therapeutic
effects
OP
remain
largely
unclear.
Methods
was
evaluated
using
public
databases
validated
our
samples.
CRISPR/Cas9,
CCK-8
assay,
transwell
assays,
oil
red
O
staining,
RNA-sequencing,
immunofluorescence
co-immunoprecipitation
(Co-IP)
vivo
experiments
were
investigate
biological
function
effect
Results
We
demonstrated
significantly
elevated
cells
tumor
tissues.
Patients
with
exhibiting
high
levels
tended
have
less
favorable
prognosis.
knockdown
inhibited
proliferation,
invasion
migration.
Subsequent
reduced
lipid
accumulation
through
promoting
perilipin
2
(PLIN2)-mediated
lipophagy.
Notably,
(NEU1
inhibitor),
promoted
lipophagy,
thereby
inhibiting
proliferation
tumorigenesis.
Moreover,
more
sensitive
compared
other
chemotherapeutics,
like
5-fluorouracil
gemcitabine,
resistance.
Conclusion
by
targeting
inducing
lipophagy
suppression
PLIN2.
Our
findings
provide
new
directions
role
offer
latent
strategies
address
chemotherapy-induced
ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 14, 2025
Inhibition
of
hepatic
stellate
cell
(HSC)
activation
and
reversal
its
state
represent
two
distinct
yet
complementary
strategies
in
antifibrotic
therapy.
While
synergy
those
is
anticipated
to
improve
the
therapeutic
outcomes,
synergism
through
nanomedicine
remains
elusive.
Herein,
we
report
a
circular
spherical
nucleic
acid
(cSNA)
with
supramolecular
core
comprising
collagenase
I
ML-290
surface
attached
PDGF-BB
aptamer
instead
stereotypical
linear
counterpart.
Unlike
conventional
inert
SNA,
this
cSNA
dissociates
response
elevated
ROS
levels
fibrotic
liver
so
that
released
disrupt
collagen
barrier
promote
penetration
ensuing
nanoparticles.
Of
significant
importance
after
circularization
exhibits
enhanced
nuclease
resistance
improved
molecular
recognition,
thereby
demonstrating
superior
capability
blocking
HSC
mediated
by
PDGF-BB/PDGFR-β
signaling.
Meanwhile,
relaxin
family
peptide
receptor
1
(RXFP1)
agonist
initially
transforms
pro-fibrogenic
macrophages
into
pro-resolution
activating
RXFP1
signaling,
facilitating
secretion
factors
for
activated
HSCs.
This
work
thus
presents
proof-of-concept
demonstration
SNA
undergoes
structural
functional
refinements,
enabling
concurrent
upstream
etiological
blockade
downstream
pathological
restoration
fibrosis.
